Evidence map›Paper›PMID 42250059›Full record

ArticleCellular oncology (Dordrecht, Netherlands)2026

P2RY6

Xin Wang, Mingyue Ma, Mingyu Zhang, Han Lu, Ying Liu, Yang Zhou, Bing Han

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cellular oncology (Dordrecht, Netherlands), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Xin WangDepartment of Breast Surgery, General Surgery Center, The First Hospital of Jilin University, Changchun City, Jilin Province, 130021, P.R. China.
Mingyue MaDepartment of Breast Surgery, General Surgery Center, The First Hospital of Jilin University, Changchun City, Jilin Province, 130021, P.R. China.
Mingyu ZhangDepartment of Breast Surgery, General Surgery Center, The First Hospital of Jilin University, Changchun City, Jilin Province, 130021, P.R. China.
Han LuDepartment of Breast Surgery, General Surgery Center, The First Hospital of Jilin University, Changchun City, Jilin Province, 130021, P.R. China.
Ying LiuDepartment of Breast Surgery, General Surgery Center, The First Hospital of Jilin University, Changchun City, Jilin Province, 130021, P.R. China.
Yang ZhouDepartment of Breast Surgery, General Surgery Center, The First Hospital of Jilin University, Changchun City, Jilin Province, 130021, P.R. China.
Bing HanDepartment of Breast Surgery, General Surgery Center, The First Hospital of Jilin University, Changchun City, Jilin Province, 130021, P.R. China. han_bing@jlu.edu.cn.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundTriple-negative breast cancer (TNBC) harbors an immunosuppressive tumor microenvironment dominated by tumor-associated macrophages (TAMs). P2RY6, a UDP-sensitive purinergic receptor, is implicated in immune modulation, but its functional role in TNBC TAMs remains elusive.

methodsThe clinical relevance of P2RY6

resultsP2RY6⁺ TAM infiltration correlates with poor prognosis in TNBC patients. UDP activation of P2RY6 drives M2-like macrophage polarization via the PLC-IP3-Ca

conclusionsOur study unveils a UDP-P2RY6-S100A9 paracrine axis wherein P2RY6⁺ TAMs foster an immunosuppressive and pro-tumorigenic niche in TNBC. This axis represents a novel therapeutic target to disrupt TAM-tumor crosstalk and overcome chemoresistance in TNBC.

Indexed as

Drug Resistance, NeoplasmMolecular Targeted TherapyReceptors, Purinergic P2Triple Negative Breast NeoplasmsTumor-Associated MacrophagesAnimalsCalgranulin BCell Line, TumorCell ProliferationFemaleHumansMiceNF-kappa BSignal TransductionToll-Like Receptor 4Tumor MicroenvironmentCalgranulin BNF-kappa Bpurinoceptor P2Y6Receptors, Purinergic P2Toll-Like Receptor 4Cancer neuroscienceMacrophage polarizationPurinergic receptorsTumor immunity

Identifiers

PMID42250059
PMCPMC13473056

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.